Literature DB >> 2002205

Carnitine, valproate, and toxicity.

D L Coulter1.   

Abstract

Carnitine is an important nutrient that is present in the diet (particularly in meat and dairy products) and is synthesized from dietary amino acids. It functions to assist long-chain fatty acid metabolism and to regulate the ratio of free coenzyme A to acylcoenzyme A in the mitochondrion. Carnitine deficiency occurs in primary inborn errors of metabolism, in nutritional deficiency, and in various other disorders including antiepileptic drug therapy. Valproate therapy is often associated with decreased carnitine levels and occasionally with true carnitine deficiency. Some experimental and clinical evidence links valproate-induced carnitine deficiency with hepatotoxicity, but this evidence is limited and inconclusive. Carnitine supplementation has been useful in some studies, but these data are also limited. Young children with neurologic disabilities taking multiple antiepileptic drugs may have the greatest risk for carnitine deficiency. Measurement of carnitine levels appears warranted in these patients and in patients with symptoms and signs of possible carnitine deficiency.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2002205     DOI: 10.1177/088307389100600102

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  24 in total

1.  Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.

Authors:  Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Nobuyuki Mishima; Yoshiyuki Kagawa; Yushi Inoue
Journal:  Eur J Clin Pharmacol       Date:  2015-09-22       Impact factor: 2.953

2.  Impaired Spatial Cognition in Adult Rats Treated with Multiple Intracerebroventricular (ICV) Infusions of the Enteric Bacterial Metabolite, Propionic Acid, and Return to Baseline After 1 Week of No Treatment: Contribution to a Rodent Model of ASD.

Authors:  Jennifer R Mepham; Francis H Boon; Kelly A Foley; Donald P Cain; Derrick F MacFabe; Klaus-Peter Ossenkopp
Journal:  Neurotox Res       Date:  2019-03-08       Impact factor: 3.911

3.  Features of Adult Hyperammonemia Not Due to Liver Failure in the ICU.

Authors:  Amra Sakusic; Moldovan Sabov; Amanda J McCambridge; Alejandro A Rabinstein; Tarun D Singh; Kumar Mukesh; Kianoush B Kashani; David Cook; Ognjen Gajic
Journal:  Crit Care Med       Date:  2018-09       Impact factor: 7.598

4.  Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.

Authors:  Ayse L Mindikoglu; Dale King; Laurence S Magder; John A Ozolek; George V Mazariegos; Benjamin L Shneider
Journal:  J Pediatr       Date:  2010-12-16       Impact factor: 4.406

5.  Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

Authors:  I Tein; S DiMauro; Z W Xie; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Childhood Epilepsy : Current Therapeutic Recommendations.

Authors:  J T Gilman; M Duchowny
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

Review 7.  Carnitine transport: pathophysiology and metabolism of known molecular defects.

Authors:  I Tein
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency.

Authors:  B Chabrol; J Mancini; D Chretien; P Rustin; A Munnich; N Pinsard
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

9.  Valproate encephalopathy and hypocarnitinaemia in diabetic patients.

Authors:  L Averbuch-Heller; T Ben-Hur; A Reches
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

10.  Effects of Low- and High-Dose Valproic Acid and Lamotrigine on the Heart in Female Rats.

Authors:  Azibe Yıldız; Nigar Vardı; Hakan Parlakpınar; Burhan Ateş; Neriman Çolakoğlu
Journal:  Cardiovasc Toxicol       Date:  2022-01-22       Impact factor: 3.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.